The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Short and medium-term outcomes of patients with solid cancer hospitalized with COVID-19 in Belgium according to cancer diagnosis and treatment characteristics.
 
Tatjana Geukens
Employment - Siemens Healthineers (I)
Leadership - Siemens Healthineers (I)
Stock and Other Ownership Interests - Siemens Healthineers (I)
 
Mariana Brandão
Speakers' Bureau - Janssen (Inst); Roche/Genentech
Research Funding - AstraZeneca (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Sanofi; Takeda
 
Marjolein Heijlen
No Relationships to Disclose
 
Joelle Collignon
Consulting or Advisory Role - Bayer (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); sanofi (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Amgen (Inst); Pfizer (Inst); Roche (Inst)
 
Cedric Van Marcke
Consulting or Advisory Role - Lilly (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bristol-Myers Squibb; Pfizer; Pfizer; Pfizer; Roche; Roche Belgium
 
Ingrid Louviaux
No Relationships to Disclose
 
Wim Demey
No Relationships to Disclose
 
Simon Van Wambeke
Consulting or Advisory Role - Janssen
 
Sylvie Lecomte
No Relationships to Disclose
 
Dominique Van Beckhoven
No Relationships to Disclose
 
Annouschka Laenen
No Relationships to Disclose
 
Jolanda Verheezen
No Relationships to Disclose
 
Sylvie Rottey
No Relationships to Disclose
 
Evandro de Azambuja
Honoraria - Libbs (Inst); Novartis/Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech; Seagen; Zodiac Pharma
Consulting or Advisory Role - Libbs; Novartis; Pierre Fabre; Roche/Genentech
Research Funding - AstraZeneca (Inst); GlaxoSmithKline/Novartis (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Roche/Genentech
 
Kevin Punie
Honoraria - Gilead Sciences (Inst); Lilly (Inst); Lilly (Inst); Mundipharma (Inst); Novartis (Inst); Novartis (Inst); Pfizer; Pfizer (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Lilly (Inst); Lilly (Inst); MSD (Inst); Novartis; Novartis; Novartis; Novartis (Inst); Novartis (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Teva (Inst); Vifor Pharma (Inst)
Research Funding - MSD (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; PharmaMar; Roche; Roche; Roche; Roche